Iodixanol Injection, USP

2022: Release of new contrast medium

On July 18, 2022, Fresenius Kabi announced the release of new contrast media - Iodixanol Injection, USP. The statement was made against the background of an acute shortage of such drugs around the world.

Iodixanol Injection, USP is the first FDA-approved generic isoosmolar dimeric iodinated contrast drug that is used in diagnostic X-ray imaging such as computed tomography.

Fresenius releases Iodixanol Injection contrast agent

Iodixanol and other contrast agents are in deficit throughout the United States due to supply chain failures associated with COVID-19. Fresenius Kabi is committed to preventing and mitigating the effects of shortages by working closely with its customers, suppliers and the FDA, as well as making long-term investments supporting the U.S. supply chain.

Contrast agents are essential for diagnosing patients. About 50 million contrast-based examinations are conducted in the United States each year, and about half of the country's hospitals have been affected by their shortage.

Iodixanol Injection, USP is bioequivalent and therapeutically equivalent to Visipaque, making it a fully replaceable brand, and is the first generic iodized contrast agent.

Fresenius Kabi is excited to help expand access to low-cost, high-quality contrast agents for the radiological community, "said John Daker, President and CEO of Fresenius Kabi USA. Approval and availability in the US of Fresenius Kabi Iodixanol Injection, USP, is expected to provide immediate relief from the current deficiency. As a company committed to the goal of "taking care of life," we are honored to help patients get the timely care they need.[1]

Notes

Шаблон:Remarks